GYRE GYRE THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1124105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.4%
TTM net income YoY-801.1%
TTM EPS YoY-2,500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin94.1%
Operating margin-20.6%
Net margin-30.1%
FCF margin-20.3%
EBITDA margin-18.8%
Returns
ROE-34.9%
ROA-20.3%
ROIC (approx.)-31.0%
Asset turnover0.68x
Leverage & solvency
Liabilities / assets17.5%
Debt / equity0.00x
Current ratio4.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $32.93M | $29.11M | $22.52M | $37.20M | $32.69M | $29.73M | $22.06M | $27.87M |
| Cost of revenue | $1.95M | $2.21M | $1.23M | $1.74M | $1.63M | $1.15M | $894,000 | $1.18M |
| Gross profit | $30.99M | $26.90M | $21.29M | $35.45M | $28.94M | $25.62M | $21.16M | $26.70M |
| R&D expense | — | — | $6.74M | $4.82M | $7.80M | $8.35M | $3.10M | $3.71M |
| SG&A expense | $8.95M | $7.86M | $7.22M | $6.70M | $6.44M | $7.28M | $4.96M | $5.46M |
| Operating income | -$1.52M | -$14.36M | -$9.36M | $118,000 | $1.49M | -$2.24M | $2.27M | $597,000 |
| Pretax income | -$1.75M | -$14.43M | -$9.24M | $7.65M | $2.52M | -$1.57M | $4.63M | $772,000 |
| Income tax | $733,000 | -$164,000 | $621,000 | $1.30M | $593,000 | $662,000 | $901,000 | $203,000 |
| Net income | -$2.48M | -$14.27M | -$18.58M | -$1.32M | $1.93M | -$2.24M | $4.94M | $598,000 |
| EBITDA | -$1.22M | -$13.26M | -$8.68M | $227,000 | $2.19M | -$1.44M | $2.81M | $1.06M |
| EPS (basic) | -0.04 | -0.12 | -0.10 | — | 0.01 | -0.02 | 0.03 | — |
| EPS (diluted) | -0.04 | -0.12 | -0.10 | — | 0.01 | -0.03 | 0.00 | — |
| Weighted avg. shares (diluted) | 106.30M | 100.64M | 91.34M | — | 103.96M | 89.20M | 101.97M | — |
| Banking | ||||||||
| Net interest income | $588,000 | $740,000 | — | -$1.00M | $954,000 | $941,000 | — | $346,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $41.64M | $43.29M | $37.50M | $49.19M | $40.40M | $36.49M | $15.04M | $11.81M |
| Short-term investments | $15.77M | $14.06M | $12.31M | $15.36M | $19.65M | $17.87M | $14.85M | $14.86M |
| Receivables | $32.66M | $27.76M | $22.76M | $31.08M | $25.88M | $24.63M | $20.15M | $19.59M |
| Inventory | $12.22M | $11.43M | $11.35M | $10.17M | $8.85M | $8.86M | $7.88M | $6.34M |
| Current assets | $123.40M | $122.07M | $91.73M | $149.36M | $98.58M | $91.28M | $68.45M | $64.79M |
| PP&E, net | $27.01M | $27.28M | $23.57M | $27.55M | $23.61M | $23.40M | $23.52M | $23.88M |
| Intangibles | $4.40M | $4.53M | $4.63M | $4.73M | $4.85M | $4.96M | $5.08M | $273,000 |
| Total assets | $201.25M | $199.25M | $162.01M | $219.76M | $159.38M | $152.65M | $129.79M | $125.41M |
| Current liabilities | $28.59M | $28.66M | $19.79M | $23.78M | $15.91M | $16.92M | $18.99M | $19.52M |
| Total liabilities | $35.18M | $34.34M | $25.03M | $31.40M | $21.97M | $23.20M | $25.49M | $27.00M |
| Shareholders' equity | $107.95M | $107.93M | $101.31M | $62.50M | $101.92M | $92.03M | $68.12M | $63.32M |
| Shares outstanding | 107.07M | 106.03M | 91.34M | 91.31M | 90.89M | 90.82M | 87.64M | 86.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.98M | -$16.73M | $3.18M | -$5.62M | -$2.58M | $2.09M | -$129,000 | -$2.76M |
| Capital expenditure | $979,000 | $262,000 | $178,000 | $144,000 | $740,000 | $256,000 | $122,000 | -$65,000 |
| Free cash flow | -$4.96M | -$16.99M | $3.00M | -$5.77M | -$3.32M | $1.83M | -$251,000 | -$2.69M |
| Investing cash flow | $1.73M | $9.76M | -$3.06M | $1.85M | $3.19M | -$3.04M | $1.97M | -$2.00M |
| Financing cash flow | $221,000 | -$8,000 | $21,000 | $318,000 | -$25,000 | $22.35M | $1.34M | $964,000 |
| Depreciation & amortization | $300,000 | $1.10M | $672,000 | $109,000 | $700,000 | $800,000 | $535,000 | $461,000 |
| Stock-based compensation | $1.73M | $1.83M | $2.58M | $4.60M | $1.33M | $1.12M | $507,000 | $567,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.